High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs - pharmacological mechanisms and clinical relevance

Thrombosis and Haemostasis

Volumn 109, Issue 5, 2013, Pages 825-833

  Hohlfeld, Thomas ^a   Saxena, Aaruni ^a   Schrör, Karsten ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Aspirin; Dipyrone; Drug interaction; Non steroidal anti inflammatory drugs; Platelet function

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; AMLODIPINE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARYLDIALKYLPHOSPHATASE 1; ATORVASTATIN; CARBOXYLESTERASE; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DILTIAZEM; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR INHIBITOR; OMEPRAZOLE; PRASUGREL; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; RIFAMPICIN; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; VERAPAMIL;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; DRUG MEGADOSE; GENETIC POLYMORPHISM; HUMAN; ISCHEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877011402     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-07-0532     Document Type: Article

References (75)

1. Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
2. Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis 2009; 52: 141-152.
3. Schrör K, Huber K, Hohlfeld T. Functional testing methods for the antiplatelet effects of aspirin. Biomark Med 2011; 5: 31-42.
4. Grinstein J, Cannon CP. Aspirin Resistance: Current Status and Role of Tailored Therapy. Clin Cardiol 2012; epub ahead of print.
5. Rocca B, Petrucci G. Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms. Thrombosis 2012; epub ahead of print.
6. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
7. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007; 120: 631-635.
8. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52: 734-739.
9. Pinto Slottow TL, Bonello L, Gavini R, et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. Am J Cardiol 2009; 104: 525-530.
10. Mannacio VA, Di Tommaso L, Antignano A, et al. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion after off-pump procedures) randomised study. Heart 2012; epub ahead of print.
11. Radovits BJ, Popa-Diaconu DA, Popa C, et al. Disease activity as a risk factor for myocardial infarction in Rheumatoid Arthritis. Ann Rheum Dis 2008; 68: 1271-1276.
12. Nadareishvili Z, Michaud K, Hallenbeck JM, et al. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 2008; 59: 1090-1096.
13. Zöller B, Li X, Sundquist J, et al. Risk of subsequent ischemic and haemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol 2012; 12: 41.
14. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12: 204-212.
15. Frelinger AL, III, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113: 2888-2896.
16. Di-Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983; 61: 1081-1085.
17. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-186.
18. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206-1211.
19. DeWitt DL, el-Harith EA, Kraemer SA, et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 1990; 265: 5192-5198.
20. 2 synthase. Nat Struct Biol 1995; 2: 637-643.
21. Llorens O, Perez JJ, Palomer A, et al. Structural basis of the dynamic mechanism of ligand binding to cyclooxygenase. Bioorg Med Chem Lett 1999; 9: 2779-2784.
22. 2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry 2001; 40: 5172-5180.
23. Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci USA 2001; 98: 14583-14588.
24. Goltsov A, Maryashkin A, Swat M, et al. Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations. Eur J Pharm Sci 2009; 36: 122-136.
25. Hong Y, Gengo FM, Rainka MM, et al. Population pharmacodynamic modeling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Clin Pharmacokinet 2008; 47: 129-137.
26. Sidhu RS, Lee JY, Yuan C, et al. Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers. Biochemistry 2010; 49: 7069-7079.
27. Smith WL, Urade Y, Jakobsson PJ. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev 2011; 111: 5821-5865.
28. Yuan C, Rieke CJ, Rimon G, et al. Partnering between monomers of cyclooxygenase-2 homodimers. Proc Natl Acad Sci USA 2006; 103: 6142-6147.
29. Prusakiewicz JJ, Duggan KC, Rouzer CA, et al. Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid. Biochemistry 2009; 48: 7353-7355.
30. Rimon G, Sidhu RS, Lauver DA, et al. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc Natl Acad Sci USA 2009; 107: 28-33.
31. Vargaftig BB. The inhibition of cyclo-oxygenase of rabbit platelets by aspirin is prevented by salicylic acid and by phenanthrolines. Eur J Pharmacol 1978; 50: 231-241.
32. Humes JL, Winter CA, Sadowski SJ, et al. Multiple sites on prostaglandin cyclooxygenase are determinants in the action of nonsteroidal anti-inflammatory agents. Proc Natl Acad Sci USA 1981; 78: 2053-2056.
33. Cerletti C, Livio M, De Gaetano G. Non-steroidal anti-inflammatory drugs react with two sites on platelet cyclo-oxygenase. Evidence from in vivo drug interaction studies in rats. Biochim Biophys Acta 1982; 714: 122-128.
34. Kaber G, Kaiser B, Baumgartel-Allekotte D, et al. Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterolfed rabbit. Br J Pharmacol 2011; 164: 561-569.
35. Fosbol EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010; 3: 395-405.
36. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. Br Med J 2011; 342:c7086.
37. Ellison J, Dager W. Recent FDA warning of the concomitant use of aspirin and ibuprofen and the effects on platelet aggregation. Prev Cardiol 2007; 10: 61-63.
38. Yuksel N, Karatas A, Ozkan Y, et al. Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2003; 56: 453-459.
39. Critchley JA, Critchley LA, Anderson PJ, et al. Differences in the single-oraldose pharmacokinetics and urinary excretion of paracetamol and its conjugates between Hong Kong Chinese and Caucasian subjects. J Clin Pharm Ther 2005; 30: 179-184.
40. Raz I, Hussein Z, Samara E, et al. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects. Int J Clin Pharmacol Ther Toxicol 1988; 26: 246-248.
41. Rolf C, Engstrom B, Beauchard C, et al. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology 1999; 38: 564-567.
42. Zhou D, Zhang Q, Lu W, et al. Single- and multiple-dose pharmacokinetic comparison of a sustained-release tablet and conventional tablets of naproxen in healthy volunteers. J Clin Pharmacol 1998; 38: 625-629.
43. Pargal A, Kelkar MG, Nayak PJ. The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations. Biopharm Drug Dispos 1996; 17: 511-519.
44. Suarez-Kurtz G, Ribeiro FM, Estrela RC, et al. Limited-sampling strategy models for estimating the pharmacokinetic parameters of 4-methylaminoantipyrine, an active metabolite of dipyrone. Braz J Med Biol Res 2001; 34: 1475-1485.
45. Rosenstock M, Danon A, Rubin M, et al. Prostaglandin H synthase-2 inhibitors interfere with prostaglandin H sythase-1 inhibition by nonsteroidal anti-inflammatory drugs. Eur J Pharmacol 2001; 412: 101-108.
46. Rosenstock M, Danon A, Rimon G. PGHS-2 inhibitors, NS-398 and DuP-697, attenuate the inhibition of PGHS-1 by aspirin and indomethacin without altering its activity. Biochim Biophys Acta 1999; 1440: 127-137.
47. Burde T, Rimon G. On the interaction of specific prostaglandin H synthase-2 inhibitors with prostaglandin H synthase-1. Eur J Pharmacol 2002; 453: 167-173.
48. Crescente M, Cerletti C, De Gaetano G. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings. Thromb Haemost 2007; 97: 1054-1056.
49. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.
50. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. JACC 2005; 45: 1295-1301.
51. Anzellotti P, Capone ML, Jeyam A, et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum 2011; 63: 850-859.
52. Gladding PA, Webster MW, Farrell HB, et al. The antiplatelet effect of six nonsteroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 2008; 101: 1060-1063.
53. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-547.
54. Hohlfeld T, Zimmermann N, Weber AA, et al. Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. J Thromb Haemost 2008; 6: 166-173.
55. Anger K, Kempfert J, Kostelka M, et al. Platelet hyporesponsiveness to acetylsalicylic acid can be transferred by plasma in humans. Pharmacology 2010; 85: 241-247.
56. Gengo FM, Rubin L, Robson M, et al. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol 2008; 48: 117-122.
57. Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 2006; 80: 264-274.
58. Snoep JD, Hovens MC, Eikelboom CJ, et al. Association of Laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. Arch Intern Med 2007; 167: 1593-1599.
59. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
60. Niccoli G, Giubilato S, Leo A, et al. Predictors of thromboxane levels in patients with non-ST-elevation acute coronary syndromes on chronic aspirin therapy. Thromb Haemost 2012; 108: 133-139.
61. Pettersen A-AR, Seljeflot I, Abdelnoor M, et al. High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: Results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Ass 2012; epub ahead of print.
62. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-3164.
63. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, et al. Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109: 3000-3006.
64. Fischer LM, Schlienger RG, Matter CM, et al. Current use of nonsteroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy 2005; 25: 503-510.
65. Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004; 43: 985-990.
66. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-574.
67. Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 2007; 66: 764-770.
68. Hennekens CH, Schneider WR, Hebert PR, et al. Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to aspirin resistance. Am Heart J 2010; 159: 744-748.
69. Ridker PM, Manson JE, Gaziano JM, et al. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114: 835-839.
70. Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos 2005; 33: 1567-1575.
71. Schuijt MP, Huntjens-Fleuren HW, de Metz M, et al. The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J Pharmacol 2009; 157: 931-934.
72. Mackenzie IS, Coughtrie MW, MacDonald TM, et al. Antiplatelet drug interactions. J Intern Med 2010; 268: 516-529.
73. Mancini JA, Riendeau D, Falgueyret JP, et al. Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J Biol Chem 1995; 270: 29372-29377.
74. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
75. Schrör K. Acetylsalicylsäure. 2 ed. Frechen: Dr. Schrör Verlag, 2011.